Preclinical activity of IRAK4 kinase inhibitor CA-4948 alone or in combination with targeted therapies and preliminary phase 1 clinical results in non-Hodgkin lymphoma Meeting Abstract
| Authors: | Booher, R. N.; Nowakowski, G. S.; Patel, K.; Lunning, M. A.; Samson, M. E. S.; Atoyan, R.; Ma, A. W.; Xu, G. X.; Dellarocca, S.; Modafferi, H.; Borek, M.; Zhang, Z.; Parker, J.; Whitney, D.; Wang, H.; Tuck, D. P.; Younes, A. |
| Abstract Title: | Preclinical activity of IRAK4 kinase inhibitor CA-4948 alone or in combination with targeted therapies and preliminary phase 1 clinical results in non-Hodgkin lymphoma |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454842803191 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-117383 |
| Notes: | Meeting Abstract: 4168 -- Source: Wos |
